Literature DB >> 2045532

The pharmacokinetics and colonic tissue concentrations of cyclosporine after i.v., oral, and enema administration.

W J Sandborn1, R M Strong, S C Forland, R E Chase, R E Cutler.   

Abstract

This study compares pharmacokinetic parameters and colonic tissue concentrations of cyclosporine administered by olive-oil or water-retention enemas with conventional intravenous (i.v.) and oral dosing. Five medical students were enrolled in a prospective crossover study. All subjects received a single dose of cyclosporine on four separate occasions, once orally, once as an olive-oil enema, once as a water enema, and once i.v. Cyclosporine concentration was measured in blood and in colonic tissue obtained by flexible sigmoidoscopy. Bioavailability was 18 +/- 7% (mean +/- SD) for the oral dose and was unmeasurable for the oil and water enemas. The concentration of cyclosporine in colon tissue was 32,443 +/- 17,251 ng/g (mean +/- SD) for the i.v. dose, 2797 +/- 1812 ng/g for the oral dose, 21,727 +/- 14,090 ng/g for the oil enema, and 25,318 +/- 30,408 ng/g for the water enema. The authors conclude that the bioavailability of cyclosporine, and thus the systemic absorption after administration by a retention enema, is negligible. The colonic tissue concentration of cyclosporine after i.v. or rectal administration via an enema is tenfold higher than that for oral dosing. These findings suggest that cyclosporine-retention enemas produce high distal colonic tissue concentrations with negligible systemic absorption after a single dose in healthy subjects and should be evaluated as treatment for patients with left-sided colitis. Because cyclosporine administered by the i.v. route provided sharply higher colonic tissue concentrations than those seen with oral therapy, pulse i.v. cyclosporine should be tried for patients with severe ileitis and colitis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2045532     DOI: 10.1002/j.1552-4604.1991.tb01890.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  11 in total

1.  Cyclosporine A inhibits interleukin-8 production in a human colon epithelial cell line (HT-29).

Authors:  O Saitoh; R Matsuse; K Sugi; K Nakagawa; K Uchida; K Maemura; K Kojima; I Hirata; K Katsu
Journal:  J Gastroenterol       Date:  1997-10       Impact factor: 7.527

Review 2.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

3.  Novel topical therapies for distal colitis.

Authors:  Ian Craig Lawrance
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-10-06

4.  Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease.

Authors:  M Latteri; G Angeloni; N G Silveri; R Manna; G Gasbarrini; P Navarra
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Efficacy of cyclosporine in treatment of fistula of Crohn's disease.

Authors:  D H Present; S Lichtiger
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

Review 6.  Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Authors:  M Schwab; U Klotz
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 7.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

8.  Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin.

Authors:  S N Murthy; H S Cooper; H Shim; R S Shah; S A Ibrahim; D J Sedergran
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

9.  Effect of cyclosporine in a murine model of experimental colitis.

Authors:  Marko Banić; Branimir Anić; Tomislav Brkić; Neven Ljubicić; Sanja Plesko; Csaba Dohoczky; Damir Erceg; Mladen Petrovecki; Igor Stipancić; Ivo Rotkvić
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.199

10.  Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis.

Authors:  Sujaata Dwadasi; Maryam Zafer; Donald Goens; Raghavendra Paknikar; Sushila Dalal; Russell D Cohen; Joel Pekow; David T Rubin; Atsushi Sakuraba; Dejan Micic
Journal:  Inflamm Bowel Dis       Date:  2021-10-18       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.